Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma

A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma

(2023) Jianghua Ding et al.   Oncology Letters

Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma

(2022) Shinya Ohata et al.   Advances in Hematology

Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications

(2020) Rouslan Kotchetkov et al.   INTERNATIONAL JOURNAL OF CANCER

Infusion-related reactions to rituximab: frequency, mechanisms and predictors

(2018) Franciane Paul et al.   Expert Review of Clinical Immunology

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

(2017) Giovanni D’Arena et al.   LEUKEMIA & LYMPHOMA

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas

(2017) Tatsuya Hayama et al.   International Journal of Clinical Pharmacy

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP

(2017) Kyoung Min Cho et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

(2016) C L Freeman et al.   LEUKEMIA

The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital

(2014) Jae-Woo Jung et al.   ONCOLOGY

Predictors of acute adverse events from rapid rituximab infusion

(2013) Dora S. P. Lang et al.   SUPPORTIVE CARE IN CANCER

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST